Other News Releases in Health Care & Hospitals
Congressman Fattah: Thanks to Specter, Casey for a Major Step Along History's Path
Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure
Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill
Other News Releases in Trade Show News
River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
U.S.-China Business Summit to Host World's Largest Symposium for Americans, Chinese
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News
Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
PT. RICHMOND, Calif., Sept. 28 /PRNewswire/ -- Transcept
Pharmaceuticals, Inc., a specialty pharmaceutical company deriving
significant new patient benefits from proven CNS drugs, today announced
that Glenn A. Oclassen, President and Chief Executive Officer, is scheduled
to present at the 2007 BIO Investor Forum at the Palace Hotel in San
Francisco on Thursday, October 11, 2007 at 3:00 PM Pacific Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
deriving significant new patient benefits from proven CNS drugs. The
company's development projects leverage new understanding of CNS conditions
to provide additional uses and enhanced clinical benefits for existing
active agents. Transcept's lead compound, Intermezzo(TM) (zolpidem tartrate
lozenge), is a low dose formulation of zolpidem that is currently in late
phase 3 clinical trials for the treatment of insomnia in patients who
awaken in the middle of the night and have difficulty returning to sleep.
TO-2060 is a novel, fixed-combination dose of olanzapine and ondansetron
that is being evaluated for the treatment of dopamine associated
psychiatric disorders (DAPD). TO-2060 is currently the subject of an
initial proof of concept trial in the treatment of alcohol use disorder
(AUD). For more information, please visit the Company's website at:
http://www.transcept.com.
SOURCE Transcept Pharmaceuticals, Inc.